key: cord-0877900-zj1pygww
authors: Maggiore, Umberto; Abramowicz, Daniel; Crespo, Marta; Mariat, Christophe; Mjoen, Geir; Peruzzi, Licia; Sever, Mehmet Sükrü; Oniscu, Gabriel C; Hilbrands, Luuk; Watschinger, Bruno
title: How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion
date: 2020-05-22
journal: Nephrol Dial Transplant
DOI: 10.1093/ndt/gfaa130
sha: f408a388d9a54121d60d39bb4263973d8fcf6fd2
doc_id: 877900
cord_uid: zj1pygww

nan

Correspondence to: Umberto Maggiore; E-mail: umberto.maggiore@unipr.it; Twitter handle: @UMaggiore, @ERAEDTA, @gabriel_oniscu, @MCrespoBarrio

After severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome-related coronavirus (MERS-CoV) in 2012, the world is now facing a third rapidly spreading coronavirus outbreak, caused by SARS-CoV-2 [1] [2] [3] . Coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization [4] and has already led to >3 million reported cases and >230 000 deaths worldwide [5] .

Viral infections pose an important risk of morbidity and mortality in patients after organ transplantation [6] . Indeed, immunosuppression, which is crucial for preventing alloimmune reactions, impairs host defense mechanisms. Respiratory virus infections, such as respiratory syncytial virus, may progress more rapidly to pneumonia in organ transplant recipients, with a tendency to more severe disease and prolonged shedding of potentially infectious virus. Immunosuppression also increases the severity of both adeno-and influenza viruses (reviewed in Razonable [7] and Manuel et al. [8] ).

With regard to COVID-19, all kidney transplant recipients (KTRs) must strictly follow the general hygiene measures recommended for the general population, including frequent hand washing, social distancing measures and wearing of masks in crowded places [9] . COVID-19 induces variable clinical courses in normal hosts but seems to progress more rapidly in immunocompromised hosts, with greater rates of intensive care unit admissions and death [10] . The largest series reported to date from Europe and the USA are shown in Table 1 [11] [12] [13] [14] [15] [16] [17] . Although there might be a bias towards selection of the most severe cases (apart from one study in which only a minority of patients had severe disease [17] ), the mortality rates were between 23% and 28%, which is close to the rate of 21% reported from a cohort of 5700 hospitalized patients in New York [18] , but certainly higher than the 5% usually reported for COVID-19-infected patients [11] . These articles describe various strategies for the management of immunosuppressive therapy, based on a stepwise reduction of immunosuppression according to the severity of the disease. Due to the heterogeneity of the reported strategies, it is of course impossible to draw generalizable conclusions about the best practice to follow.

A European initiative, promoted by ERA-EDTA and the DESCARTES working group (WG) has recently started and is aiming to rapidly collect data about treatments and outcomes of COVID-19 disease in KTRs [9]. In the meantime, how to deal with immunosuppression among KTRs is left to clinical judgement and common sense, taking into consideration the risk of a serious, potentially fatal disease along with the risk of acute rejection and possibly graft loss. Interestingly, none of the series has reported acute rejection and graft loss as a consequence of immunosuppression reduction ( might be due to a too-short follow-up period. Furthermore, with KTRs amounting to only 0.1% of the general population, it is unlikely that evidence-based medicine will ever be produced for KTRs infected with COVID-19. Indeed, while >1000 studies about COVID-19 are registered in ClinicalTrials.gov (accessed 1 May 2020), none is devoted specifically to treatment of KTRs. While in vitro experiments suggest that coronavirus may require intact immunophilin pathways with a role for tacrolimus and cyclosporine to inhibit the growth of human coronaviruses [19, 20] , the translation of these experimental findings in clinics remains to be seen. There is also the fear that complete withdrawal of immunosuppressive drugs may exacerbate the hyperinflammatory response that may occur in the late stages of COVID-19. After reading the expert opinions published by single centres (Table 1 ) and societies (French [21] , Spanish [22] , British [23] , American [24] ), and after extensive discussions between its members, the DESCARTES WG formulated suggestions for COVID-19-infected KTRs who are beyond 3-6 months after kidney transplantation ( Table 2) .

Treatment of COVID-19 is based on antiviral drugs that inhibit SARS-CoV-2 proliferation and on immunomodulatory drugs that inhibit the hyperinflammatory syndrome that may cause adacute respiratory distress syndrome (ARDS) and lifethreatening respiratory failure [25, 26] . In theory, antiviral drugs could be effective in restraining viral infection when given in the early phase of the infection, whereas immunomodulatory Stop MPA/AZA/mTORi Maintain on dual therapy CNI-steroids Reduce CNI trough levels to target CsA: 50 6 15 ng/mL, Tac: 3 6 1 ng/mL Continue steroids in maintenance dose In patients starting antiretroviral treatment: stop CNI and monitor as detailed in the text Cautiously restart previous immunosuppression 5-10 days after symptoms have cleared 5. More severe COVID-19 pneumonia: oxygen saturation <94% in room air, respiratory rate 30/min, unstable or deteriorating course or requiring non-invasive ventilation or transfer to the intensive care unit (with or without mechanical ventilation) Discontinue all immunosuppressive drugs Increase/start steroids at 15-25 mg/day (or higher according to local practice). Consider continuing with low-dose CNI in patients with higher risk of rejection (e.g. <1 year after transplantation and/or highly immunized) Cautiously restart previous immunosuppression (CNI first) 5-15 days after symptoms have cleared When available, risk stratification may additionally benefit from the results of lab parameters indicating severe inflammatory disease at risk of rapid progression, such as a high level of C-reactive protein, IL-6, ferritin and D-dimer. MPA, mycophenolate mofetil, mycophenolic acid; AZA, azathioprine; CsA, cyclosporine; Tac, tacrolimus.

Editorial drugs may show the strongest benefit when administered during the late hyperinflammatory phase of the disease. Herein we do not formulate any advice on the use of antiviral drugs, antibiotics or anti-inflammatory drugs in KTRs with COVID-19. For these issues, please refer to your infectivologist and local and/or national guidelines. Below, we discuss anti-COVID-19 therapies in the context of renal impairment and their potential effects on the exposure of concomitant immunosuppressive agents.

Remdesivir Remdesivir, which is administered intravenously, has a favourable clinical profile and no known drug-to-drug interactions (DDIs). However, the drug has not been studied in patients with kidney failure [estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m 2 ], which has been an exclusion criterion so far [27] .

Although a much-cited source [28] indicates that there is a possible increase in the exposure of cyclosporine, tacrolimus and mammalian target of rapamycin inhibitors (mTORis) during simultaneous use of chloroquine/hydroxychloroquine, a thorough PubMed search retrieved only two cases of increased cyclosporine levels. As chloroquine/hydroxychloroquine, which have a long half-life, are given for only 5-7 days, it is preferable but not mandatory to follow the trough levels of cyclosporine, tacrolimus and mTORis in this setting. No dose adjustment is mandatory in patients with kidney failure (eGFR <30 mL/min/ 1.73 m 2 ), although it is recommended to use with caution in this setting.

Complete withdrawal of calcineurin inhibitor (CNI) and mTORi should be considered in every patient undergoing treatment with ritonavir-or cobicistat-boosted antiviral drugs. In fact, tacrolimus should be reduced to 1/20-1/50 in patients receiving ritonavir (and to 1/10 in patients receiving cobicistat) of the initial dose just to maintain constant blood levels [29, 30] . Therefore the dose should be reduced even further (i.e. even <1/50 of the initial dose) if the therapeutic plan is to 'reduce' CNIs rather than stop them. If the treatment with ritonavir-/ cobicistat-based drugs is planned for only 5-7 days, then CNIs (and mTORis) should be withdrawn altogether and restarted no earlier than 24-48 h after ritonavir/cobicistat discontinuation at low dose. For longer ritonavir/cobicistat treatments (e.g. 2 weeks [31] ), tacrolimus blood levels should be monitored daily and oral tacrolimus 0.5 mg/day administered only after blood levels have dropped below the desired lower bound (e.g. <5 ng/mL). It should also be noted that the hepatic clearance of tacrolimus may be further reduced in the course of multiple organ failure, making tacrolimus dose adjustments even more challenging. DDIs are milder for cyclosporine compared with tacrolimus, the dose reduction usually being 1/5 to maintain constant blood levels. No dose adjustment of lopinavir-ritonavir, darunavir-cobicistat is needed for renal failure. Nonetheless, it should be mentioned that a randomized trial on the use of lopinavir-ritonavir failed to show a clear benefit [31] ; therefore, given the high risk of the DDIs in this category of patients, we recommend against their routine use in KTRs.

Besides counteracting severe inflammation causing inflammatory lung injury and thrombotic complications in COVID-19, anti-inflammatory drugs in transplant recipients may have the additional benefit of protecting against rejection in patients who have withdrawn CNIs because of severe disease. However, they should be used with caution since suppression of inflammatory responses in the absence of effective antiviral therapy may cause uncontrolled infection [10] .

A randomized controlled trial is testing the safety/efficacy of steroids (NCT04273321). Until results are available, broad use of high-dose steroids is discouraged [32] . However, for the treatment of a hyperinflammatory state causing abrupt respiratory compromise, and in the absence of viable alternatives, their use may be considered on a case-by-case basis [33] [34] [35] , even in KTRs.

Tocilizumab and other anti-interleukin (IL)-6/IL-6R monoclonal antibodies (e.g. sarilumab)

After the preliminary successful experience of its use in China [36] , and pending results from various clinical trials, tocilizumab is currently the most popular treatment used to counteract hyperinflammatory syndrome causing impending or ongoing respiratory compromise. In this severe clinical setting, usually transplant recipients had already withdrawn mycophenolate/azathioprine/mTORi along with CNIs before they were considered for tocilizumab administration. Tocilizumab should be used with caution if the white blood cell count is <1000/mm 3 . Its elimination is not influenced by renal dysfunction.

High-dose intravenous immunoglobulins have been proposed for the use in patients with COVID-19 and deteriorating conditions to counteract inflammation and endothelial activation [37] .

At the time of writing, clinical trials are ongoing for the evaluation of other promising antiviral drugs and anti-inflammatory drugs such as favipiravir [25, 26] , umifenovir (arbidol) [25, 26, nelfinavir [25] , ivermectin [38] , baricitinib [a Janus kinase (JAK) inhibitor] [38] , anakinra (an IL-1 receptor antagonist)

[39] and colchicine [40] . Favipiravir and arbidol do not need to be adjusted for renal function. CYP3A4 is the major isoform involved in arbidol metabolism, therefore there may be potential interaction, especially in patients taking cyclosporine and mTORi. In contrast, favipiravir does not have DDIs with CNIs and mTORi [26] . Baricitinib [25] is contraindicated with kidney failure (eGFR <30 mL/min/1.73 m 2 ) and may strongly increase the risk of infections in association with CNIs. Anakinra does not have DDIs with CNIs and mTORis and should be given every other day in patients with kidney failure (eGFR <30 mL/ min/1.73 m 2 ).Colchicine is better avoided while the patient is receiving concurrent treatment with ritonavir-cobicistat-based antiviral therapy and its dose should be halved in patients with kidney failure (eGFR <30 mL/min/1.73 m 2 ). DDIs with tacrolimus are likely to be negligible, whereas concomitant administration of cyclosporine may warrant monitoring.

Convalescent plasma therapy and hyperimmune immunoglobulins, namely the transfer of passive immunity from convalescent human plasma, offer the most promising novel therapeutic approaches for the treatment of COVID-19 [41, 42] .

None declared.

A cluster of cases of severe acute respiratory syndrome in Hong Kong

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

A novel coronavirus from patients with pneumonia in China

WHO declares COVID-19 a pandemic

Infections in solid-organ transplant recipients

Management of viral infections in solid organ transplant recipients

Influenza and other respiratory virus infections in solid organ transplant recipients

Novel coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve

Covid-19 and kidney transplantation

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

Early description of coronavirus 2019 disease in kidney transplant recipients in New York

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia

COVID-19 infection in kidney transplant recipients

Kidney allograft recipients diagnosed with coronavirus disease-2019: a single center report

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication

Prise en charge de l'infection due au SARS-CoV-2 chez les patients adultes transplantés d'organe solide 2020

Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients

Guidance on the management of transplant recipients diagnosed with or suspected of having COVID19

American Society of Transplantation. 2019-nCoV (Coronavirus): FAQs for organ donation and transplantation

Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Compassionate use of remdesivir for patients with severe COVID-19

COVID-19 drug interactions

Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review

Combination drug products for HIV-A word of caution for the transplant clinician

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

COVID-19: consider cytokine storm syndromes and immunosuppression

On the use of corticosteroids for 2019-nCoV pneumonia

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality

High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

COVID-19 in kidney transplant recipients

Convalescent plasma as a potential therapy for COVID-19

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Correspondence to: Rajiv Agarwal; E-mail: ragarwal@iu.edu

An author video to accompany this article is available at: https://academic.oup.com/ndt/.The acute crisis with the coronavirus disease of 2019 (COVID-19) caused by the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) is the largest biomedical catastrophe of our lifetimes. Like so many other disasters in the past, such as war, famine, social unrest and economic calamities, this too shall pass, but it will undoubtedly leave the world changed. Some of the changes are already evident, but some are inevitable once we get over this pandemic. In this perspective, I provide examples of how the virus is already inducing change in the practice of medicine at large and for nephrology in particular. As is true for many changes, some persist after the emergency is over, so I speculate on how nephrology may change once we surmount this predicament ( Figure 1 ).

In the worldwide fight against an invisible enemy, the world has learned incredible new ways to collaborate. Within days after the epidemic unfolded in North America, two young physicians, Matthew Sparks and Swapnil Hiremath, curated an annotated resource for use by nephrologists [1] . With a group of colleagues, they were among the first to address the question of whether angiotensin-converting enzyme inhibitors or angiotensin receptor blockers should be stopped in patients who are taking these drugs. Their answer-which was to continue to take these medications-was later supported both by a statement from the European Society of Cardiology [2] and a scholarly review in the New England Journal of Medicine [3] . In the context of the epidemic, under the umbrella of the World